TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03820336

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil
Description: Subjects will consume 45 ml (40 g) of EVOO daily for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Oil
Description: Subjects will consume 45 ml (40 g) of a control sunflower seed oil daily for 8 weeks.
Study: NCT04547998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Intervention (UVB)
Description: Targeted narrowband-UVB phototherapy in alignment with published Vitiligo Working Group recommendations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)
Description: Spray-On Skin™ Cells prepared using RECELL will be applied to an area prepared by ablative laser, followed by targeted narrowband UVB phototherapy.
Study: NCT04401904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: 10 participants randomized to receive 12 weeks of daily dapagliflozin 10mg by mouth

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutritional counseling
Description: 10 participants randomized to receive 12 weeks of weekly counseling on nutrition
Study: NCT00425074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: slow release acetyl salicylic acid
Description: 150 mg in capsules via oral, during 14 days.
Study: NCT02539862

Intervention type: OTHER
Group type: OTHER
Intervention: psychoeducation
Description: the psychoeducation is delivered by a doctor
Study: NCT02173717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 150 mg Dabigatran etexilate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: 600 mg Rifampicin
Study: NCT00425074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: normal release acetylsalicylic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR-ASA
Description: slow release acetylsalicylic acid 150 mg
Study: NCT00282867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV glucose insulin and potassium, GIK
Description: The treatment intervention includes glucose, insulin, potassium infusion or standard therapy.
Study: NCT00289783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine
Description: 3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine
Description: 3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
Study: NCT00282867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV glucose insulin and potassium, GIK
Description: The treatment intervention includes glucose, insulin, potassium infusion or standard therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: usual care
Study: NCT01866345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgically facilitated Orthodontic treatment
Description: Surgically facilitated Orthodontic treatment in the mandibular anterior region

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional orthodontic treatment
Description: Conventional orthodontic Procedure
Study: NCT00981747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil 20mg three times per day for 3 months followed by a one month washout prior to next intervention.
Study: NCT02471534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominal compression
Description: When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
Study: NCT00981747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan 25mg two times a day for 3 months followed by a one month washout prior to next intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil and Losartan
Description: Sildenafil 20mg three times per day and Losartan 25mg two times per day followed by a one month washout prior to next intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo pill three times per day for 3 months followed by a one month washout prior to next intervention.
Study: NCT04319913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: analgesia nociception index
Description: Analgesia nociception index (ANI) could objectively monitor how pain the participant is. In the experimental group, the care provider would decrease the dose of narcotics (remifentanil) if the ANI value is above 70, and increase the dose if the ANI value is under 50.
Study: NCT01097525

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WFG PRK
Study: NCT00422903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: 1500 mg administered orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: 2.5 mg administered orally daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: letrozole
Description: 2.5 mg administered orally daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1500 mg administered orally daily
Study: NCT01662557

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Behavior Modification
Description: 5-month intervention for parents and children providing 15 sessions in behavioral skills training in self monitoring, Traffic Light Diet, goal setting, reinforcement and tasting sessions. Of the 15 sessions, 3 were structured as phone sessions.
Study: NCT01097525

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WFG LASIK

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WFO PRK

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WFO LASIK
Study: NCT03717714

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine 1500 mg
Description: Patients in this group take 3 capsules, each capsule contains Placebo 16.7mg and Glucosamine 500 mg, once a day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polycan 50mg + Glucosamine 750 mg
Description: Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 250 mg, once a day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polycan 50mg + Glucosamine 1500 mg
Description: Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
Study: NCT04589416

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental adhesive materials.
Description: It is used to bond the composite resin to the dental tissues. That is, it is used to bond dental filling materials to dental tissues.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental adhesive materials.
Description: It is used to bond the composite resin to the dental tissues. That is, it is used to bond dental filling materials to dental tissues.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental adhesive materials.
Description: It is used to bond the composite resin to the dental tissues. That is, it is used to bond dental filling materials to dental tissues.
Study: NCT02782793

Intervention type: PROCEDURE
Intervention: Endoscopic Mucosal Resection
Study: NCT02008786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramipril
Description: 5-10mg (starting dose 5mg titrating up to 10mg if tolerated after 1 week)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: 10-20mg (suggested dose 10mg for Asians, 20mg for everyone else)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo
Study: NCT01662557

Intervention type: OTHER
Group type: OTHER
Intervention: Minimal Nutrition Information
Description: Families assigned to MNI received a series of 15 mailings on topics related identifying a healthy body weight for children; energy balance and calorie requirements for children; MyPyramid for Kids; portion control; the benefits of physical activity and screen-time reduction; encouraging fruit and vegetable consumption; healthy snacks and smart shopping; and encouraging family meals.
Study: NCT03775824

Intervention type: DRUG
Intervention: MTX start
Description: Patient prescribed MTX s.c. or p.o. because of active rheumatoid arthritis

Intervention type: DRUG
Intervention: TNF start
Description: Patient prescribed TNF-inhibitor because of active rheumatoid arthritis
Study: NCT04165408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contino
Description: The Contino® urethral insert is a self-administered licensed medical device, is inserted into the distal portion of the male urethra inhibiting the flow of urine. The Contino is self-inserted into the adult male urethra and is removed prior to urination. Much more than just a device, Contino® is an integrated solution that includes personalised fitting and support from incontinence specialists. It is made from highly specialised medical grade polymer, which has been extensively tested for biocompatibility.
Study: NCT03423303

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Prostate cancer screening
Description: Depending on each diagnostic test result the participants in the screening arm will undergo PSA-testing, 4Kscore determination, MRI, and MRI/US fusion biopsy only.
Study: NCT02758119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serious Game

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online course
Study: NCT00088972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT03558971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortisol
Description: Participants determine when to administer 5-day regimens of cortisol
Study: NCT02961504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLCM051
Description: Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of 1.2 billion HLCM051 cells to be intravenously administered

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of placebo to be intravenously administered
Study: NCT02709577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier Gastrointestinal Liner
Description: The EndoBarrier is a single use, implant consisting of a tube of composite material which is placed in the proximal section of the duodenum. The implant is fixed in place with the aid of a metal anchor. The device is delivered via an endoscope. The implant facilitates the passage of food from the stomach through the tube to the proximal section of the jejunum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham: endoscopy and standard of care
Description: Sham subjects had an endoscopic procedure and then received standard of care treatment of their diabetes
Study: NCT00333411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 2584 XX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 2584 XX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRT 2584 XX

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01642056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-743
Description: This medication is used to treat disorders of energy metabolism such as mitochondrial diseases. It does not correct the inherited disorder of energy metabolism or mitochondrial diseases. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EPI-743
Description: This medication is used to treat disorders of energy metabolism such as mitochondrial diseases. It does not correct the inherited disorder of energy metabolism or mitochondrial diseases. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00289783

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB
Description: 3-dose intramuscular injection at 2, 4 and 6 months of age.
Study: NCT02468960

Intervention type: DEVICE
Group type: OTHER
Intervention: Predilatation with OPN NC balloon catheter.
Description: Target lesion will be prepared by predilatation with OPN NC balloon catheter.

Intervention type: DEVICE
Group type: OTHER
Intervention: Predilatation with standard compliant balloon.
Description: Target lesion will be prepared by predilatation with standard balloon catheter (compliant).
Study: NCT01642056

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02468960

Intervention type: DEVICE
Group type: OTHER
Intervention: Absorb BVS implantation.
Description: After lesion preparation implantation of BVS Absorb scaffold will be performed.
Study: NCT01230190

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ecologic ® Panda II
Description: Probiotic strains: 3 Bifidobacteria, 3 Lactococci, 1\*10\^9 Colony Forming Units/g.~Composition: rice starch, maltodextrins, bacterial strains and mix of minerals.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: rice starch, maltodextrins, and mix of minerals. The placebo mixture is similar in aspect, consistency and taste as Ecologic ® Panda II (intervention).
Study: NCT01689987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO
Study: NCT02468960

Intervention type: DEVICE
Group type: OTHER
Intervention: Absorb BVS implantation.
Description: After lesion preparation implantation of BVS Absorb scaffold will be performed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Treated segment visualization by OCT.
Description: Finally treated segment will be visualized by Intravascular Optical Coherence Tomography (OCT).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Treated segment visualization by OCT.
Description: Finally treated segment will be visualized by Intravascular Optical Coherence Tomography (OCT).

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical FU at 12 months.
Description: All patients will be clinically followed for 12 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical FU at 12 months.
Description: All patients will be clinically followed for 12 months.
Study: NCT01689987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01854489

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The volunteers will be given Oral placebo at 20.00 for 7 days \[Phase 1 \]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
Study: NCT02476344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experiment protocol
Description: each subject will perform the following 3 days experiment protocol, consisting of army training exercises:~1. sack carrying exercise.~2. crawling exercise.~3. combined exercise: sack carrying, crawling and sprints.~heart rate, core temperature, lactic acid and CPK levels will be monitored continuously.
Study: NCT01689987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study: NCT00289783

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PedvaxHIB
Description: 1 booster dose by intramuscular injection at 12 to 15 months of age.
Study: NCT02669394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Twelve months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control: stretching and relaxation program
Description: Twelve months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
Study: NCT01875393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOOKAD® Soluble
Description: The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.
Study: NCT03569787

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI Pituitary
Description: Identification of whether of not patients had had an MRI pituitary following hyperprolactinaemia reading
Study: NCT03757624

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shrinkage
Description: shrinkage of gastric specimen in %10 formol solution after Laparoscopic Sleeve Gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shrinkage
Description: shrinkage of gastric specimen in %10 formol solution after Laparoscopic Sleeve Gastrectomy
Study: NCT03376139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
Study: NCT01413295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dendritic Cell Vaccine
Description: Vaccination with autologous dendritic cells loaded with autologous tumor antigens
Study: NCT01478178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-083 (Dianhydrogalactitol)
Description: VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
Study: NCT00326157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AmBisome
Description: 3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment (day 50-8th Week) of AmBisome®, IV administration
Study: NCT03271307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimized PITC
Description: Providers will receive training on the importance of HIV testing and their role in testing as part of OPD care and morning HIV testing will be offered. Providers will receive job aids on the importance of referring patients for HIV testing, and the study team will conduct regular monitoring and evaluation on PITC implementation.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Facility HIVST
Description: HIVST will be carried out in a group setting among patients in the waiting area of OPD clinics. Eligible clients will receive education about HIV testing and a demonstration of how to use and interpret results of a self-test kit will occur in the group setting. Participants will use the HIVST kit in a group setting and will be given private settings (private room or booth) to interpret their results. Participants will disclose their results to their OPD provider if they choose. Routine linkage to confirmatory testing and ART initiation will be conducted.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Index HIVST
Description: HIVST demonstration and distribution will be provided to HIV-positive clients in participating facilities to distribute to their partners. Partners who have a reactive HIVST test result, or are unable or unwilling to use HIVST, will be asked to present at the health facility for routine HIV testing. Routine linkage to confirmatory testing and ART initiation will be conducted.
Study: NCT02784977

Intervention type: DEVICE
Intervention: Positive Airway Pressure (PAP)
Description: Treatment of OSA with PAP

Intervention type: DEVICE
Intervention: Intraoral device (IOD)
Description: Treatment of OSA with IOD
Study: NCT00289783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix
Description: 3-dose intramuscular injection at 2, 4 and 6 months of age.
Study: NCT02784977

Intervention type: PROCEDURE
Intervention: Uvuloplasty
Description: Uvuloplasty

Intervention type: OTHER
Intervention: Conservative treatment
Description: No active intervention
Study: NCT01721512

Intervention type: OTHER
Intervention: Breastfeeding

Intervention type: OTHER
Intervention: Infant formula
Study: NCT04686877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STAPLE
Description: Stereotactic aspiration plus urokinase clot irrigation
Study: NCT01413295

Intervention type: OTHER
Group type: OTHER
Intervention: Supportive treatment
Description: Supportive treatment after progression of the illness after 2 lines of chemotherapy
Study: NCT01279291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KHK2866
Description: Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.
Study: NCT00289783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix
Description: 3-dose intramuscular injection at 2, 4 and 6 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix
Description: 3-dose intramuscular injection at 2, 4 and 6 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix
Description: 3-dose intramuscular injection at 2, 4 and 6 months of age.